MiR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway. Issue 14 (18th July 2019)

• Record Type: Journal Article
• Authors: Xia, Liang; Wu, Linlin; Xia, Hailong; Bao, Jing; Li, Qingsheng; Chen, Xiaowen; Xia, Ruixiang
• Is Part Of: Cell cycle. Volume 18:Issue 14(2019)
• Page Start: 1635
• Page End: 1645
• Publication Date: 2019-07-18
• Subjects: Cutaneous T-cell lymphoma -- miR-337 -- metastasis; Cell cycle -- Periodicals; 571.84377
• DOI: 10.1080/15384101.2019.1629789
• Languages: English
• ISSNs: 1538-4101

Abstract

ABSTRACT: Cutaneous T-cell lymphoma (CTCL) is associated with the downregulation of miR-337 expression, although the exact underlying mechanism is unknown. In the present work, we investigated the molecular mechanism and function of miR-337 in regulating CTCL cell viability and invasion. We observed that miR-337 expression was downregulated in both CTCL tumors and cell lines. Furthermore, CCK assay, BrdU incorporation assay, and flow cytometry revealed that transfection with the miR-337 mimic resulted in decreased proliferation and increased apoptotic levels in CTCL cells. Results of the Transwell migration assay indicated that the miR-337 mimic decreased CTCL cell invasion in vitro . Both bioinformatics prediction and the dual-luciferase reporter assay revealed that miR-337 targets the 3′-UTR of STAT3 for silencing. Overexpression of STAT3 counteracted the pro-apoptotic influence of miR-337 in CTCL cell lines and restored their invasion properties. The results thus indicate that the miR-337-STAT3 axis inhibits the proliferation of malignant T cells and that miR-337 may serve as a promising therapeutic target for CTCL.